EXHIBIT 99.7

    VASO ACTIVE REVAMPS ITS EXISTING AND ADOPTS NEW CORPORATE GOVERANNCE AND
                              COMPLIANCE POLICIES


DANVERS, Mass.--(BUSINESS WIRE)--January 25, 2005 -- Vaso Active
Pharmaceuticals, Inc. (Vaso Active) (VAPH.pk) of Danvers, Massachusetts,
announced today on January 19, 2005, the Company's Board of Directors revised
certain existing and approved new corporate governance policies and procedures
of the Company. Specifically, the Board adopted Compensation Committee and
Nominating and Corporate Governance Charters; made revisions to the existing
Audit Committee Charter and Code of Ethics; adopted Policies and Procedures
Regarding Shareholder Communications with the Board of Directors, and Nominating
and Corporate Governance Committee Policies and Procedures for the Consideration
of Board of Director Candidates. The purpose of this Board action was to
strengthen the Company's corporate governance and compliance structures and to
reiterate the Board's commitment to fostering sound and reliable corporate
governance environment.

"These newly adopted policies and procedures provide ethical, operational and
compliance guidelines for our management and employees alike. As the Company
continues to mature and evolve, our Board is committed to strengthening the
corporate governance and compliance culture within our Company. This is a
significant and timely step in that direction," said Joseph Frattaroli, Acting
CEO of Vaso Active.


FORWARD-LOOKING STATEMENTS

         Certain statements contained herein constitute "forward-looking
statements" within the meaning of the Private Securities Litigation Reform Act
of 1995. These forward-looking statements are based on current expectations,
estimates and projections about the Company's industry, management's beliefs and
certain assumptions made by management. Readers are cautioned that any such
forward-looking statements are not guarantees of future performance and are
subject to certain risks, uncertainties and assumptions that are difficult to
predict. Because such statements involve risks and uncertainties, the actual
results and performance of the Company may differ materially from the results
expressed or implied by such forward-looking statements. Given these
uncertainties, readers are cautioned not to place undue reliance on such
forward-looking statements. Unless otherwise required by law, the Company also
disclaims any obligation to update its view of any such risks or uncertainties
or to announce publicly the result of any revisions to the forward-looking
statements made here; however, readers should review carefully reports of
documents the Company files periodically with the SEC.

Contact:

Matt Carter
Vaso Active Pharmaceuticals, Inc.
978-750-1991 Ext. 28
mcarter@vasoactive.us